FAE Stock Overview
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.52 |
| 52 Week High | €3.54 |
| 52 Week Low | €2.87 |
| Beta | 0.47 |
| 1 Month Change | 11.75% |
| 3 Month Change | 14.85% |
| 1 Year Change | 4.45% |
| 3 Year Change | 0.057% |
| 5 Year Change | -11.78% |
| Change since IPO | 247.17% |
Recent News & Updates
Recent updates
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Shareholder Returns
| FAE | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | 2.0% | 1.1% | 1.6% |
| 1Y | 4.5% | 40.0% | 16.8% |
Return vs Industry: FAE underperformed the Spanish Pharmaceuticals industry which returned 40% over the past year.
Return vs Market: FAE underperformed the Spanish Market which returned 16.8% over the past year.
Price Volatility
| FAE volatility | |
|---|---|
| FAE Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.9% |
| 10% least volatile stocks in ES Market | 1.1% |
Stable Share Price: FAE has not had significant price volatility in the past 3 months.
Volatility Over Time: FAE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,748 | n/a | faesfarma.com |
Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and markets pharmaceutical products and raw materials in Spain and internationally. The company's products include prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn’s disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu.
Faes Farma, S.A. Fundamentals Summary
| FAE fundamental statistics | |
|---|---|
| Market cap | €1.10b |
| Earnings (TTM) | €94.75m |
| Revenue (TTM) | €482.06m |
11.6x
P/E Ratio2.3x
P/S RatioIs FAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAE income statement (TTM) | |
|---|---|
| Revenue | €482.06m |
| Cost of Revenue | €163.56m |
| Gross Profit | €318.50m |
| Other Expenses | €223.75m |
| Earnings | €94.75m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 66.07% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 3.2% |
How did FAE perform over the long term?
See historical performance and comparison